Biktarvy is a prescription antiretroviral medication formulated as a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide. It is indicated for the treatment of HIV-1 infection in adults and adolescents, offering a once-daily regimen that helps suppress viral load and maintain immune function.

Key Features:

• Contains bictegravir, emtricitabine, and tenofovir alafenamide in a single tablet for simplified therapy.
• Once-daily dosing enhances adherence and convenience.
• Demonstrated efficacy in suppressing HIV-1 viral load and increasing CD4+ cell counts.
• Well-tolerated with a favorable safety profile in clinical studies.
• Supports long-term viral suppression and immune system preservation.

Recommended Usage:

• Adults and adolescents (≥12 years and weighing ≥35 kg) with HIV-1 infection.
• Dosage: One tablet orally once daily, with or without food, as prescribed by a healthcare provider.
• Do not discontinue therapy without consulting a physician, as interruption may lead to viral resistance.
• Routine monitoring of renal function, liver enzymes, and viral load is recommended during treatment.